Jensa Morris: Why Low Molecular Weight Heparins Should Be the First Choice for VTE
Jensa Morris, Director of Smilow Hospitalist Service at Yale New Haven Hospital, shared a post on LinkedIn about a recent article by Youssef Saklawi et al, published in Journal of Hospital Medicine, adding:
“There are so many clinical interventions that we do reflexively despite a mountain of clinical evidence to the contrary.
Thank you Journal of Hospital Medicine and TWDFNR for reminding us that LMWH and not UFH should be first choice for patients requiring non-oral treatment for VTE, even for those who may later require thrombolysis or thrombectomy.”
Title: Things we do for no reason™: Routine use of unfractionated heparin for initial anticoagulation in venous thromboembolism
Authors: Youssef Saklawi, Mohamad Ali Tfaily, Bhargav Marthambadi, Adrian Umpierrez
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 28, 2026, 03:57Sara Zalghout: Navigating the Often-Unspoken Challenges of Academia at ISTH 2026
-
Jun 28, 2026, 02:56Carlo Alfieri: Redefining Anemia Management After Kidney Transplantation
-
Jun 28, 2026, 02:36Ramesh Chennupat: Anemia is Associated with Increased REV Release in Stable Coronary Artery Disease
-
Jun 28, 2026, 02:01RishiRaj Sinha: Driving the Future of Transfusion Medicine Through Global Collaboration at ISBT 2026
-
Jun 27, 2026, 18:19Nabil Tabish: The Paradox of Zero – Investigating Extreme VWF Discordance
-
Jun 27, 2026, 18:19Francesco Favruzzo: Can Mechanical Thrombectomy Be Safely Used in Cervical Artery Dissection?
-
Jun 27, 2026, 18:18Vera Ghali: 2026 ASH–ISTH Recommendations on Pediatric VTE Prevention
-
Jun 27, 2026, 18:17Michiel Coppens: A Hemostasis Laboratory – One of the Cornerstones of Our Hemophilia Mission
-
Jun 27, 2026, 18:16Sthanu Subramanian: Dabigatran and Mechanical Heart Valves